Manvi Sharma1, Holly M Holmes2,3, Hemalkumar B Mehta3,4, Hua Chen3, Rajender R Aparasu3, Ya-Chen T Shih5, Sharon H Giordano5, Michael L Johnson3. 1. Department of Pharmacy Administration, The University of Mississippi, Oxford, Mississippi. 2. Division of Geriatric and Palliative Medicine, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas. 3. Department of Pharmaceutical Health Outcomes and Policy, University of Houston, Houston, Texas. 4. Department of Surgery, The University of Texas Medical Branch, Galveston, Texas. 5. Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: The concomitant use of tyrosine kinase inhibitors (TKIs) and proton pump inhibitors (PPIs) is a significant concern because of potential drug-drug interaction that reduces TKI absorption, thus potentially reducing the effectiveness of TKIs. The objective of this study was to evaluate the prevalence and predictors of concomitant TKI-PPI receipt and its impact on survival and therapy discontinuation in older adults with cancer. METHODS: This retrospective study used linked Surveillance, Epidemiology, and End Results-Medicare data for the years 2007 through 2012. In total, 12,538 patients with lung cancer, renal cell cancer, chronic myelogenous leukemia, liver cancer, or pancreatic cancer were included. The primary exposure variable was concomitant receipt of TKI-PPI, defined as at least 30 days of PPI use in the first 90 days from the start of the TKI (exposure period). The outcomes measured were overall survival and discontinuation of therapy in 90 days and 1 year after the end of the exposure period. Cox proportional-hazards regression with inverse probability of treatment weighting was used to evaluate the association between exposure and outcome. RESULTS: The overall prevalence of TKI-PPI receipt was 22.7%. Predictors that were associated with increased use included polypharmacy and prior PPI receipt. TKI-PPI use decreased survival in 90 days (hazard ratio, 1.16; 95% confidence interval, 1.05-1.28) and in 1 year (hazard ratio, 1.10; 95% confidence interval, 1.04-1.18) but was not associated with discontinuation. CONCLUSIONS: Nearly 1 in 4 older adults with cancer who receive TKIs also receive PPIs concomitantly, and concomitant use is associated with an increased risk of death. Concerted efforts to manage medications are needed to identify and reduce the receipt of PPIs when TKIs are initiated.
BACKGROUND: The concomitant use of tyrosine kinase inhibitors (TKIs) and proton pump inhibitors (PPIs) is a significant concern because of potential drug-drug interaction that reduces TKI absorption, thus potentially reducing the effectiveness of TKIs. The objective of this study was to evaluate the prevalence and predictors of concomitant TKI-PPI receipt and its impact on survival and therapy discontinuation in older adults with cancer. METHODS: This retrospective study used linked Surveillance, Epidemiology, and End Results-Medicare data for the years 2007 through 2012. In total, 12,538 patients with lung cancer, renal cell cancer, chronic myelogenous leukemia, liver cancer, or pancreatic cancer were included. The primary exposure variable was concomitant receipt of TKI-PPI, defined as at least 30 days of PPI use in the first 90 days from the start of the TKI (exposure period). The outcomes measured were overall survival and discontinuation of therapy in 90 days and 1 year after the end of the exposure period. Cox proportional-hazards regression with inverse probability of treatment weighting was used to evaluate the association between exposure and outcome. RESULTS: The overall prevalence of TKI-PPI receipt was 22.7%. Predictors that were associated with increased use included polypharmacy and prior PPI receipt. TKI-PPI use decreased survival in 90 days (hazard ratio, 1.16; 95% confidence interval, 1.05-1.28) and in 1 year (hazard ratio, 1.10; 95% confidence interval, 1.04-1.18) but was not associated with discontinuation. CONCLUSIONS: Nearly 1 in 4 older adults with cancer who receive TKIs also receive PPIs concomitantly, and concomitant use is associated with an increased risk of death. Concerted efforts to manage medications are needed to identify and reduce the receipt of PPIs when TKIs are initiated.
Authors: Michael P Chu; Sunita Ghosh; Carole R Chambers; Naveen Basappa; Charles A Butts; Quincy Chu; David Fenton; Anil A Joy; Randeep Sangha; Michael Smylie; Michael B Sawyer Journal: Clin Lung Cancer Date: 2014-08-15 Impact factor: 4.785
Authors: Vincent H Ha; Margaret Ngo; Michael P Chu; Sunita Ghosh; Michael B Sawyer; Carole R Chambers Journal: J Oncol Pharm Pract Date: 2014-03-24 Impact factor: 1.809
Authors: Clara J K Lam; Lindsey Enewold; Timothy S McNeel; Dolly P White; Joan L Warren; Angela B Mariotto Journal: J Natl Cancer Inst Monogr Date: 2020-05-01
Authors: F Ranchon; C Rioufol; H Prely; C Herledan; A G Caffin; A Baudouin; V Larbre; M Maire; V Schwiertz; N Vantard Journal: J Cancer Res Clin Oncol Date: 2021-04-29 Impact factor: 4.553